Illumina advances MRD research portfolio with ultrasensitive duplex sequencing technology
Article excerpt
Early access program launches to support ultrasensitive research into molecular residual disease and tumor evolution. New chemistry is optimized for highest possible accuracy, with reproducible detection of ctDNA at 2.5 parts per million levels with low sample input (10 nanograms) in representative studies SAN DIEGO, Nov. 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN ) today announced an expansion of its molecular residual disease (MRD) research portfolio with an early access program for an ultrasensitive sequencing workflow. Designed to detect trace amounts of circulating tumor DNA (ctDNA) in plasma samples, the workflow's duplex chemistry analyzes both strands of a DNA molecule to increase confidence in detection. It combines the latest sequencing and software advances from the NovaSeq X platform and DRAGEN bioinformatics software to support longitudinal, whole-genome studies of MRD. "Researchers need effective ways to find the faintest traces of tumor DNA - signals that can be especially difficult to detect in early-stage, low-shedding, or low-mutation-burden tumors," said Cande Rogert, vice president, Global Head of Advanced Science, Illumina. "This early access technology is an important step toward helping researchers explore those challenging settings with greater sensitivity and generate evidence that can advance MRD research." The new duplex sequencing...
Keep reading with a free account
The rest of this article, and every signal for Illumina, is in your free account.
Extracted from this sentence
Kits for the early access program are expected to ship in the first quarter of 2027.